Evidence map›Paper›PMID 41638924›Full record

ArticleEBioMedicine2026

Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in preclinical mouse models.

Yoshiaki Tanji, Shu Shimada, Megumi Kato, Yoshimitsu Akiyama, Megumi Hatano, Shu Tsukihara, Yosuke Igarashi, Keita Kodera, Kohei Okazaki, Koya Yasukawa and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yoshiaki TanjiDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan; Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Shu ShimadaDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan. Electronic address: shimada.monc@tmd.ac.jp.
Megumi KatoDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan.
Yoshimitsu AkiyamaDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan.
Megumi HatanoDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan.
Shu TsukiharaDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan; Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Yosuke IgarashiDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan; Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Keita KoderaDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan; Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Kohei OkazakiDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan; Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Koya YasukawaDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan; Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Kentaro UmemuraDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan; Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Atsushi KamachiDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan; Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Atsushi NaraDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan; Department of Hepato-Biliary-Pancreatic Surgery, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan.
Masahiro YamaneDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan; Department of Hepato-Biliary-Pancreatic Surgery, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan.
Yoshiya IshikawaDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan; Department of Hepato-Biliary-Pancreatic Surgery, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan.
Erika MochizukiDepartment of Advanced Nanomedical Engineering, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan.
Yuki MochidaDepartment of Advanced Nanomedical Engineering, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan.
Toru IkegamiDivision of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Daisuke BanDepartment of Hepato-Biliary-Pancreatic Surgery, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan.
Satoshi UchidaDepartment of Advanced Nanomedical Engineering, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan.
Shinji TanakaDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan. Electronic address: tanaka.monc@tmd.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) with peritoneal dissemination is highly refractory to chemotherapy and immunotherapy, leading to poor prognosis. We aimed to develop an innovative therapeutic approach for advanced PDAC.

methodsWe performed comprehensive analyses of 498 bulk and 99 single-cell RNA-sequencing datasets. We established a syngeneic mouse model for subcutaneous and intraperitoneal metastatic tumours using mouse Kras

findingsThe aggressive PDAC subtype exhibited a paucity of dendritic cells (DCs) and T cells, causing an immunosuppressive tumour microenvironment. The syngeneic mouse model recapitulated this immunological phenotype with resistance to conventional systemic therapies. The MIMIC therapy not only significantly reduced the local tumour burden but also elicited a robust abscopal effect, suppressing distant peritoneal metastases and prolonging survival (P < 0.001). The omission of any single agent from the MIMIC regimen substantially abrogated the therapeutic efficacy. Flow cytometry and immunohistochemical analyses revealed that the MIMIC treatment enhanced immunogenic cell death, increased peripheral CD44+ CD62L- effector memory T cells, induced intratumoural infiltration of CD11c+ DCs and CD8+ T cells, and expanded TCR repertoire diversity.

interpretationCombining cytokine mRNA immunotherapy with cytotoxic killing and immune checkpoint blockade can reactivate antitumour immunity, offering a promising strategy for treating advanced PDAC.

fundingThis work was supported by Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), Japan Agency for Medical Research and Development (AMED), and the Princess Takamatsu Cancer Research Fund.

Indexed as

CytokinesDendritic CellsPancreatic NeoplasmsRNA, MessengerT-LymphocytesAnimalsCell Line, TumorDisease Models, AnimalHumansImmunotherapyMiceTumor MicroenvironmentCytokinesRNA, MessengerAbscopal effectCancer-immunity cycleCytokine mRNA-based therapyPancreatic carcinomaPeritoneal metastasis

Identifiers

PMID41638924
PMCPMC12988560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.